Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 10;60(8):1295.
doi: 10.3390/medicina60081295.

Prospective Assessment of Serum Lipid Alterations in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals: Insights Six Months Post Sustained Virological Response

Oana Koppandi  1   2 , Dana Iovănescu  1 , Bogdan Miuțescu  3   4 , Alexandru Cătălin Motofelea  5 , Oana Maria Jigău  1   2 , Andreea Iulia Papoi  1   2 , Călin Burciu  1   3   4 , Eyad Gadour  6   7 , Deiana Vuletici  3   4 , Eftimie Miuțescu  1   2
Affiliations

Prospective Assessment of Serum Lipid Alterations in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals: Insights Six Months Post Sustained Virological Response

Oana Koppandi et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Chronic hepatitis C virus (HCV) infection is intricately linked with dysregulation of lipid metabolism. In particular, cholesterol plays a crucial role in HCV replication. Direct-acting antiviral agents (DAAs) therapy has revolutionized the hepatitis C treatment landscape, achieving high rates of sustained virological response (SVR). However, viral clearance comes with some alterations in lipid-related markers. This prospective study aimed to evaluate the impact of HCV clearance on lipid homeostasis and non-invasive liver fibrosis markers in hepatitis C patients treated with DAAs. Material and Methods: Fifty-two patients with varying degrees of fibrosis treated with DAAs therapy were evaluated at baseline and 24 weeks post-SVR. Lipid profiles and non-invasive liver fibrosis markers were assessed. Results: Our findings revealed an increase in total cholesterol, triglyceride, and LDLc (low-density lipoprotein cholesterol) levels at 24 weeks post-SVR, alongside an improvement in serum liver enzymes. Although improvements in liver stiffness were observed in non-invasive tests, there was an increase in lipid-related markers post-SVR. Conclusions: This suggests a potential increased cardiovascular risk despite improvements in liver function and fibrosis, highlighting the necessity for statin therapy in some cases and extended follow-ups for these patients. These findings underscore the importance of closely monitoring lipid profiles in chronic hepatitis C patients post-SVR, as well as the potential need for statin therapy to mitigate cardiovascular risk. Additionally, extended follow-up is essential to assess long-term outcomes and ensure the optimal management of these patients.

Keywords: chronic hepatitis C; direct-acting antiviral agents; lipids; liver fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Prevalence of comorbid conditions.
See this image and copyright information in PMC

References

    1. World Health Organization . Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. WHO; Geneva. Switzerland: 2017. [(accessed on 17 February 2024)]. Available online: https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-....
    1. European Centre for Disease Prevention and Control . Prevention of Hepatitis B and C in the EU/EEA. ECDC; Stockholm, Switzerland: 2022. [(accessed on 17 February 2024)]. Available online: https://www.ecdc.europa.eu/en/publications-data/prevention-hepatitis-b-a....
    1. Cooke G.S., Andrieux-Meyer I., Applegate T.L., Atun R., Burry J.R., Cheinquer H., Dusheiko G., Feld J.J., Gore C., Griswold M.G., et al. Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol. Hepatol. 2019;4:135–184. doi: 10.1016/S2468-1253(18)30270-X. - DOI - PubMed
    1. Madaliński K., Zakrzewska K., Kołakowska A., Godzik P. Epidemiology of HCV infection in Central and Eastern Europe. Prz. Epidemiol. 2015;69:459. - PubMed
    1. Huiban L., Stanciu C., Muzica C.M., Cuciureanu T., Chiriac S., Zenovia S., Burduloi V.M., Petrea O., Sîngeap A.M., Gîrleanu I., et al. Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania—A Population-Based Screening—The First Step to Viral Micro-Elimination. Healthcare. 2021;9:651. doi: 10.3390/healthcare9060651. - DOI - PMC - PubMed

LinkOut - more resources